Hemin

Identification

Name
Hemin
Accession Number
DB03404
Description

Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • chloro(protoporphyrinato)iron(III)
  • Hämin
  • Hemina
  • hémine
  • protohemin

Pharmacology

Indication

Used in the management of porphyria attacks, particularly in acute intermittent porphyria.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabHemin may increase the anticoagulant activities of Abciximab.
AcenocoumarolHemin may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidHemin may increase the anticoagulant activities of Acetylsalicylic acid.
AlteplaseHemin may increase the anticoagulant activities of Alteplase.
AncrodHemin may increase the anticoagulant activities of Ancrod.
AnistreplaseHemin may increase the anticoagulant activities of Anistreplase.
Antithrombin AlfaHemin may increase the anticoagulant activities of Antithrombin Alfa.
Antithrombin III humanHemin may increase the anticoagulant activities of Antithrombin III human.
ApixabanHemin may increase the anticoagulant activities of Apixaban.
ArdeparinHemin may increase the anticoagulant activities of Ardeparin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PanhematinInjection, powder, lyophilized, for solution7 mg/1mLIntravenousRecordati Rare Diseases Inc1983-07-202020-01-24US flag
PanhematinPowder, for solution268 mgIntravenousRecordati Rare Diseases Canada Inc2018-12-05Not applicableCanada flag
PanhematinInjection, powder, lyophilized, for solution7 mg/1mLIntravenousLundbeck Inc.1983-07-202013-07-18US flag
PanhematinPowder, for solution7 mg/1mLIntravenousRecordati Rare Diseases Inc1983-07-20Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
B06AB01 — Hemin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
743LRP9S7N
CAS number
16009-13-5

References

General References
Not Available
Human Metabolome Database
HMDB00887
KEGG Compound
C06767
PubChem Substance
46504761
ChemSpider
401223
RxNav
5175
ChEBI
50385
RxList
RxList Drug Page
Wikipedia
Hemin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionGraft Failure / Ischemia-Reperfusion Injury1
2Active Not RecruitingTreatmentPorphyrias, Acute1
2CompletedTreatmentDiabetes Mellitus / Gastroparesis1
2RecruitingPreventionAcute Intermittent Porphyria (AIP) / Coproporphyria, Hereditary / Variegate Porphyria1
2RecruitingTreatmentPost-ERCP Acute Pancreatitis1
2TerminatedTreatmentMyelodysplastic Syndrome1
1CompletedNot AvailableHealthy Volunteers1
Not AvailableActive Not RecruitingNot AvailableAcute Intermittent Porphyria (AIP) / Coproporphyria, Hereditary / Variegate Porphyria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution, concentrateIntravenous25 mg/ml
Injection, powder, lyophilized, for solutionIntravenous7 mg/1mL
Powder, for solutionIntravenous268 mg
Powder, for solutionIntravenous7 mg/1mL
PowderIntravenous350 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates